Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes
about
sameAs
LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.Finding new tricks for old drugs: an efficient route for public-sector drug discovery.Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor.Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine.Serotonin receptors and heart valve disease--it was meant 2B.II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine.Native serotonin 5-HT2C receptors are expressed as homodimers on the apical surface of choroid plexus epithelial cellsDivergent effects of the 'biased' 5-HT1 A receptor agonists F15599 and F13714 in a novel object pattern separation task.Dopamine receptors and Parkinson's diseaseDevelopment, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.Negative lens-induced myopia in infant monkeys: effects of high ambient lightingGDNF--a potential target to treat addiction.Role of dopamine agonists in Parkinson's disease: an update.Apomorphine therapy in Parkinson's disease: a review.Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings.2-Bromoterguride-a potential atypical antipsychotic drug without metabolic effects in rats.Review of Presentation, Diagnosis and Management of Pituitary Tumours in Pregnancy.Cardiovascular effects of noncardiovascular drugs.A unique population of ventral tegmental area neurons inhibits the lateral habenula to promote reward.The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.Dopamine receptor agonists for Parkinson's disease.Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.Suppression of metastasis by mirtazapine via restoration of the Lin-7C/β-catenin pathway in human cancer cellsMolecular dynamics simulations and docking studies on 3D models of the heterodimeric and homodimeric 5-HT(2A) receptor subtype.Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia.Screening for valve disease in patients with hyperprolactinaemia disorders prescribed cabergoline: a service evaluation and literature review.Mechanisms of G protein activation via the D2 dopamine receptor: evidence for persistent receptor/G protein interaction after agonist stimulation.The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux.Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.Bromocriptine use and the risk of valvular heart disease.Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking.Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.Chronic cluster-like headache in a patient with a macroprolactinoma presenting with falsely low prolactin levels: bromocriptine versus cabergoline?Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.Drug-induced serotonin syndrome: a review.
P2860
Q30484494-509F5C18-6AF1-4349-805D-CDED70352D40Q33229063-146A76F0-1031-46A2-B5D7-A780FF0EC0A6Q33465315-C70E5CDA-9B48-4CE9-BF6D-44C6D6767D76Q33954437-278CB33C-8D7F-4A79-B04D-4B290C39C9A8Q33973748-09CB4DA3-CAE6-4F1E-B826-CE41B8580562Q34173511-9CE3BA10-9782-437E-8148-1291E8F51B90Q34210759-1C4F2D19-5D85-404D-805F-2CFF6CA55411Q35040501-DD7F43E2-C7F4-4069-B47C-2A31DB9AD8F2Q35198061-960170EF-F475-428B-B4BC-6570BB6D770BQ35538516-B1808BBD-95D5-44F6-9038-2F76BC7E51A4Q35545020-D579D774-E965-40A8-BE1A-848D4C0A6233Q36223175-E54D9635-C101-4E48-9497-AFE130D89DA7Q36544945-E77B8507-B8B8-457D-B75C-4B802F645B27Q36777115-0C079869-A436-42B3-9DC5-3EB3A3ABA162Q36801997-8F2B792D-CAAB-48C5-9998-2A90076EB63DQ36928841-EB6B0068-C386-43EE-8181-58C21D9EE0BBQ36972701-ED53F765-D1F4-4199-AD57-F7CAB7019B73Q36979329-494566C8-2063-45E1-B921-90A3A0ADD74DQ37064021-D58C46F5-19B9-4BE1-A6D9-C07BCB802BD0Q37067125-BE8E7641-FDDB-4B61-9A40-F0567E430D05Q37315349-D8142DB7-6FA2-4E27-BDBC-5B817B348851Q37413163-C2C8C546-5D59-4C87-A5DC-B61E5E9AC653Q37416157-CF09BB4F-095C-4949-853F-C7733A2F8E2FQ37889252-8EDDF5CF-26D6-4901-9F27-5D63E1D281A4Q38169202-1A3DF609-743C-4FBB-80BB-9DA174A60148Q38877254-516E611D-468E-422F-911B-FAF290171C2AQ38981661-83994427-8D9B-4D16-901D-8DC66F7DB2BAQ39752554-39655604-CFAA-443F-80CF-CE37B07C140CQ41061757-ECF8BE10-3D51-4DEC-8D93-5BD79403EE09Q41473311-57CC092A-021A-45AA-AE7C-846ABFE0994FQ41556713-E790D8DA-80DD-40D9-A61B-6AD95ADED80CQ44693038-32E81BA7-2C1B-49A4-87BE-24C3439CAD33Q45349712-09B6D2D2-C85E-461A-9EC5-807ABCA54F76Q46260213-9277B392-B416-4E6C-9647-1A470C3E08BAQ46587545-CDB10663-119F-4419-8345-1CCD32675E41Q46884153-279A6A51-FBD0-4AA2-8181-696DC7084982Q47148747-0D02A824-1A89-4365-9539-E257DEDA2D28Q48614497-B8B26E4E-8661-4248-AF16-84ED5D12613CQ51886952-A22EA63C-6239-4E4E-A167-BE09A74E1137
P2860
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Differential actions of antipa ...... and 5-HT(2), receptor subtypes
@ast
Differential actions of antipa ...... and 5-HT(2), receptor subtypes
@en
Differential actions of antipa ...... and 5-HT(2), receptor subtypes
@nl
type
label
Differential actions of antipa ...... and 5-HT(2), receptor subtypes
@ast
Differential actions of antipa ...... and 5-HT(2), receptor subtypes
@en
Differential actions of antipa ...... and 5-HT(2), receptor subtypes
@nl
prefLabel
Differential actions of antipa ...... and 5-HT(2), receptor subtypes
@ast
Differential actions of antipa ...... and 5-HT(2), receptor subtypes
@en
Differential actions of antipa ...... and 5-HT(2), receptor subtypes
@nl
P2093
P3181
P356
P1476
Differential actions of antipa ...... and 5-HT(2), receptor subtypes
@en
P2093
Didier Cussac
Laurence Verrièle
Manuelle Touzard
Mark J Millan
Nathalie Carpentier
Yann Quentric
P304
P3181
P356
10.1124/JPET.102.039883
P407
P577
2002-11-01T00:00:00Z